Local Injection of Dexamethasone Acetate Suspension into the Nasal Mucosa in Cases of Olfactory Disturbance.

Fukazawa, Keijiro; Fujii, Megumi; Tomofuji, Seiichi; Ogasawara, Hiroshi; Seo, Wataru; Sakagami, Masafumi

doi:10.3950/jibiinkoka.102.1175

Cited by 6 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hotchkiss ( 41 ) reported that oral glucocorticoid improves olfactory dysfunction induced by nasal polyps. Moreover, Fukazawa et al ( 42 ) gave nasal septum mucosal local injection of dexamethasone to 102 patients with a different etiology of olfactory disorder, and 63.7% patients demonstrated an improved sense of smell. Finally, Guan et al ( 24 ) used intranasal pneumatic jet atomization inhalation of budesonide suspension for the treatment of patients with olfactory dysfunction with different causes, and achieved better therapeutic effects.…”

Section: Discussionmentioning

confidence: 99%

Intranasal application of glucocorticoid alleviates olfactory dysfunction in mice with allergic rhinitis

Wang

Zhu

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

The aim of the present study was to investigate the effect of glucocorticoid intervention on olfactory dysfunction in mice with allergic rhinitis (AR). An AR animal model was established by intraperitoneal injection and intranasal application of ovalbumin to mice. The olfactory function of the mice was evaluated using a buried food test, and morphological changes in the nasal mucosa were determined using hematoxylin and eosin staining. The expression of olfactory marker protein (OMP) in the olfactory mucosa was tested by immunohistochemistry, and was observed on days 7 and 14 after the application of glucocorticoid. The incidence rate of olfactory dysfunction in AR mice was 75.34%, and the olfactory epithelium became thinner in mice with AR compared to the control group. In addition, the expression of OMP in the olfactory epithelium was downregulated in mice with AR compared with the control group. Expression of OMP in the olfactory epithelium was upregulated in the budesonide group A and betamethasone group A compared with the medicine-free group, whereas the expression of OMP in the olfactory epithelium of budesonide group A or betamethasone group A was not significantly different from the control group. Moreover, the expression of OMP in the budesonide group B was similar to budesonide group A, and expression of OMP in betamethasone group B was similar to betamethasone group A. The expression of OMP in olfactory mucosa is downregulated in AR mice with olfactory dysfunction. Following the application of glucocorticoid, the expression of OMP in the olfactory mucosa in mice is upregulated. Moreover, intranasal local glucocorticoid has a low incidence of systemic adverse reactions, and is recommended for the treatment of olfactory dysfunction in AR.

show abstract

Section: Discussionmentioning

confidence: 99%

Intranasal application of glucocorticoid alleviates olfactory dysfunction in mice with allergic rhinitis

Wang

Zhu

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Therapeutic trials involving steroids have shown that the oral administration of prednisolone may improve olfactory function in some patients 6 , 7 . Previous studies have also reported that mecobalamin (vitamin B12) 8 , 9 and G biloba 10 – 12 may have potential benefits in recovering olfactory function. Thus, the main treatment for post-traumatic olfactory dysfunction at our institute is a tapered course of oral steroids, followed by mecobalamin and G biloba thereafter.…”

Section: Discussionmentioning

confidence: 99%

“…The treatment strategy at our institute was to use a tapered course of oral prednisolone, 6 , 7 and mecobalamin (vitamin B12), 8 , 9 followed by treatment with Ginkgo biloba 10 – 12 . The dosage of prednisolone was tapered over a period of four weeks, as follows: 30 mg/day in the first week, 20 mg/day in the second week, 10 mg/day in the third week and 5 mg/day in the last week.…”

Section: Methodsmentioning

confidence: 99%

Risk of decline and chance of improvement in olfaction among patients with post-traumatic olfactory loss

Shu

2015

J. Laryngol. Otol.

View full text Add to dashboard Cite

show abstract

“…Injecting the steroid into the nasal mucosa near the olfactory cleft should be slowly spread in the nasal mucosa near the olfactory cleft, thus being effective at the local area. In Japan, it was found that there was an improvement in half of the patients with anosmia within the onset of 1 year [8].…”

Section: Introductionmentioning

confidence: 99%

Olfactory mucosa steroid injection in treatment of post-COVID-19 olfactory dysfunction: a randomized control trial

Lasheen,

Abou-Zeid

2023

Egypt J Otolaryngol

View full text Add to dashboard Cite

Background Olfactory dysfunction can be a troublesome condition affecting the quality of life of the patient. Post-viral olfactory dysfunction is the most common cause attributing to up to 40% of anosmia. COVID-19 infection commonly causes anosmia in 30–66% of patients. The long-term effect of post-COVID olfactory dysfunction is reported to be increasing in incidence. Steroids are usually used in the treatment of olfactory dysfunction and most commonly used locally in the form of nasal steroid sprays, rinses, or drops. Oral systemic steroids are sometimes used; however, they have several known side effects. Other treatments experimented include giving vitamins, minerals, antioxidants, antivirals, and monoclonal antibodies, in addition to olfactory training, counseling, and acupuncture. In this study, the effect of intranasal steroid injection is studied in post-COVID olfactory dysfunction. Results Forty patients with olfactory dysfunction post-COVID-19 for more than 3 months were randomly divided into 2 groups. Group A patients received 8 doses of dexamethasone over 2 months (twice weekly) injected near the olfactory mucosa in the nasal septum and middle turbinate, compared to group B who received saline injected in the same way as placebo. Numerically, nasal injection of corticosteroids in group A showed more subjective improvement using the questionnaire of olfactory disorders-negative statement QOD-NS than the control patients in group B but this improvement was statistically insignificant. Conclusion The use of intranasal corticosteroids injection should be considered in the treatment of post-COVID anosmia.

show abstract

Local Injection of Dexamethasone Acetate Suspension into the Nasal Mucosa in Cases of Olfactory Disturbance.

Cited by 6 publications

References 4 publications

Intranasal application of glucocorticoid alleviates olfactory dysfunction in mice with allergic rhinitis

Intranasal application of glucocorticoid alleviates olfactory dysfunction in mice with allergic rhinitis

Risk of decline and chance of improvement in olfaction among patients with post-traumatic olfactory loss

Olfactory mucosa steroid injection in treatment of post-COVID-19 olfactory dysfunction: a randomized control trial

Contact Info

Product

Resources

About